Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma

Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer of the elderly, with high metastatic potential and poor prognosis. In particular, the primary resistance to immune checkpoint inhibitors (ICI) in metastatic (m)MCC patients represents a challenge not yet met by any efficient treatment modal...

Full description

Bibliographic Details
Main Authors: Alexandra Aicher, Anca Sindrilaru, Diana Crisan, Wolfgang Thaiss, Jochen Steinacker, Meinrad Beer, Thomas Wiegel, Karin Scharffetter-Kochanek, Ambros J. Beer, Vikas Prasad
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Pharmaceutics
Subjects:
radiotherapy
immunotherapy
checkpoint inhibitors
anti-PD-1
neuroendocrine tumors
Online Access:https://www.mdpi.com/1999-4923/14/7/1466

Internet

https://www.mdpi.com/1999-4923/14/7/1466

Similar Items